表紙
市場調查報告書

促血紅細胞生長素 (EPO) 藥市場分析:藥物類別 (生技藥品,生物仿製藥),產品 (紅血球生成素Alpha,紅血球生成素β,Darbepoetin-alfa(長效紅血球生成素),其他),各用途,市場區隔預測

Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 515350
出版日期 內容資訊 英文 100 Pages
商品交期: 2-3個工作天內
價格
Back to Top
促血紅細胞生長素 (EPO) 藥市場分析:藥物類別 (生技藥品,生物仿製藥),產品 (紅血球生成素Alpha,紅血球生成素β,Darbepoetin-alfa(長效紅血球生成素),其他),各用途,市場區隔預測 Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025
出版日期: 2017年05月29日內容資訊: 英文 100 Pages
簡介

本報告提供全球促血紅細胞生長素 (EPO) 藥市場相關調查,彙整市場概要和各類藥物,各產品,各用途,各地區預測與趨勢,及打入市場的主要企業簡介等資料。

第1章 調查方法與調查範圍

第2章 摘要整理

第3章 市場變數,趨勢,範圍

  • 市場區隔及範圍
    • 推動市場的要素分析
    • 阻礙市場的要素
  • 優先的主要機會
  • SWOT分析
  • 產業分析:波特分析

第4章 各類藥物預測

  • 各類藥物趨勢分析
  • 生技藥品
  • 生物仿製藥

第5章 各產品預測與趨勢分析

  • 趨勢分析
  • 紅血球生成素Alpha
  • 紅血球生成素β
  • Darbepoetin-alfa
  • 其他

第6章 各用途預測與趨勢分析

  • 趨勢分析
  • 癌症
  • 血液學
  • 腎臟疾病
  • 神經科

第7章 各地區預測與趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第8章 企業簡介

  • 策略架構
  • 市場進入
  • 企業簡介
    • Johnson & Johnson
    • elltrion, Inc.
    • Teva Pharmaceutical Industries Ltd
    • Amgen, Inc.
    • F. Hoffman-La Roche Ltd.
    • LG Life Sciences Ltd.
    • Biocon Limited
    • Intas Pharmaceuticals Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.

圖表

目錄
Product Code: GVR-1-68038-861-9

The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cancer resulting in anemia is a major growth driver of this market.

According to the statistics published by the National Heart, Lung, and Blood Institute of the U.S. Department of Health & Human Services, over 3 million people are affected by anemia every year and this number is expected to increase over the forecast period. This showcases the need for erythropoietin-stimulating agents in the coming years.

Introduction of novel drugs and their cheaper biosimilar formulations with enhanced efficacy and cost-effectiveness is also expected to serve this industry with lucrative opportunities. For instance, development of numerous biosimilars in the European market is expected to gain traction and increase their usage rates, owing to associated benefits such as less time required for approval, cost-efficiency, and enhanced therapeutic effect.

Companies are involved in extensive R&D initiatives for development of innovative molecules and discovering new therapeutic areas for existing drugs. For instance, in April 2016, Sandoz received approval from the European Commission for use of its biosimilar Binocrit in nephrology indications, thereby extending the therapeutic area of its product portfolio.

Moreover, many of the industry players in the U.S., Europe, and Asia Pacific are involved in the development of new biosimilars. For example, Biocon's subsidiary Syngene International entered into an agreement with Bristol-Myers Squibb to extend their drug discovery and development program in India. This enables Biocon to enhance its erythropoietin drugs portfolio. Expected product approvals in the coming years are anticipated to fuel market growth.

Further key findings from the study suggest:

The biologics segment is declining over the forecast period owing to patent expiration of branded biologics and introduction of biosimilars in the market

The patent for Aranesp (darbepoetin-alfa) will expire in 2024 in the U.S. and is expected to provide numerous future growth opportunities for new market entrants

Epoetin-alfa held the largest share of product segment owing to its early introduction in the U.S. market and patent protection

Epoetin-omega and epoetin-zeta are anticipated to exhibit lucrative growth over the forecast period owing to associated benefits such as longer half-life and enhanced therapeutic effects

Use of erythropoietin drugs for treatment of renal diseases held a dominant share as of 2016 owing to the increasing incidence of chronic kidney diseases

The Asia Pacific regional industry for erythropoietin-stimulating agents is expected to witness lucrative CAGR during the forecast period

Industry participants are focusing on the discovery of new therapeutic areas for existing drugs and development of cost-effective biosimilars, thereby increasing R&D activities for the development of erythropoietin drugs.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Country wise market: Base estimates
    • 1.1.1 Global market: CAGR calculation
    • 1.1.2 Region based segment share calculation
  • 1.2 Research Scope & Assumptions
  • 1.3 List of Data Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Erythropoietin Drugs Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Increasing incidences of chronic diseases
    • 3.2.2 Patent expiration of branded drugs
  • 3.3 Market Restraint Analysis
    • 3.3.1 High cost of erythropoietin drugs in developing countries
  • 3.4 Key Opportunities Prioritized
    • 3.4.1 Key opportunities prioritized, by product
  • 3.5 Erythropoietin Drugs - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.6 Industry Analysis - Porter's

Chapter 4 Erythropoietin Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1 Erythropoietin Drugs Market: Drug Class Movement Analysis
  • 4.2 Biologics
    • 4.2.1 Biologics market, 2014 - 2025 (USD Million)
  • 4.3 Biosimilars
    • 4.3.1 Biosimilars market, 2014 - 2025 (USD Million)

Chapter 5 Erythropoietin Drugs Market: Product Estimates & Trend Analysis

  • 5.1 Erythropoietin Drugs Market: Product Movement Analysis
  • 5.2 Epoetin-alfa
    • 5.2.1 Epoetin-alfa market, 2014 - 2025 (USD Million)
  • 5.3 Epoetin-beta
    • 5.3.1 Epoetin-beta market, 2014 - 2025 (USD Million)
  • 5.4 Darbepoetin-alfa
    • 5.4.1 Darbepoetin-alfa market, 2014 - 2025 (USD Million)
  • 5.5 Others
    • 5.5.1 Others market, 2014 - 2025 (USD Million)

Chapter 6 Erythropoietin Drugs Market: Application Estimates & Trend Analysis

  • 6.1 Erythropoietin DrugsMarket: Application Movement Analysis
  • 6.2 Cancer
    • 6.2.1 Cancer market, 2014 - 2025 (USD Million)
  • 6.3 Hematology
    • 6.3.1 Hematology market, 2014 - 2025 (USD Million)
  • 6.4 Renal Diseases
    • 6.4.1 Renal diseases market, 2014 - 2025 (USD Million)
  • 6.5 Neurology
    • 6.5.1 Neurology Market, 2014 - 2025 (USD Million)

Chapter 7 Erythropoietin Drugs Market: Regional Estimates & Trend Analysis, by Drug Class, Product, and Application

  • 7.1 Erythropoietin Drugs Market Share by Region, 2016 & 2025
  • 7.2 North America
    • 7.2.1 North America erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
    • 7.2.2 North America erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
    • 7.2.3 North America erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
    • 7.2.4 North America erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.2.5 U.S.
      • 7.2.5.1 U.S. erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.2.5.2 U.S. erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.2.5.3 U.S. erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.2.6 Canada
      • 7.2.6.1 Canada erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.2.6.2 Canada erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.2.6.3 Canada erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
    • 7.3.2 Europe erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
    • 7.3.3 Europe erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
    • 7.3.4 Europe erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.3.5 Germany
      • 7.3.5.1 Germany erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.3.5.2 Germany erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.3.5.3 Germany erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.3.6 UK
      • 7.3.6.1 UK erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.3.6.2 UK erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.3.6.3 UK erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
    • 7.4.2 Asia Pacific erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
    • 7.4.3 Asia Pacific erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
    • 7.4.4 Asia Pacific erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.4.5 Japan
      • 7.4.5.1 Japan erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.4.5.2 Japan erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.4.5.3 Japan erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.4.6 China
      • 7.4.6.1 China erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.4.6.2 China erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.4.6.3 China erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.4.7 India
      • 7.4.7.1 India erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.4.7.2 India erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.4.7.3 India erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
      • 7.5.1.1 Latin America erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.5.1.2 Latin America erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.5.1.3 Latin America erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.5.2.2 Brazil erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.5.2.3 Brazil erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.5.3.2 Mexico erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.5.3.3 Mexico erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • 7.6 MEA
    • 7.6.1 MEA erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
    • 7.6.2 MEA erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
    • 7.6.3 MEA erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
    • 7.6.4 MEA erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
    • 7.6.5 South Africa
      • 7.6.5.1 South Africa erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
      • 7.6.5.2 South Africa erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
      • 7.6.5.3 South Africa erythropoietin drugs market, by application, 2014 - 2025 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Market Participation
  • 8.3 Company Profiles
    • 8.3.1 Johnson & Johnson
      • 8.3.1.1 Company overview
      • 8.3.1.2 Financial performance
      • 8.3.1.3 Product benchmarking
      • 8.3.1.4 Strategic initiatives
    • 8.3.2 Celltrion, Inc.
      • 8.3.2.1 Company overview
      • 8.3.2.2 Financial performance
      • 8.3.2.3 Product benchmarking
      • 8.3.2.4 Strategic initiatives
    • 8.3.3 Teva Pharmaceutical Industries Ltd
      • 8.3.3.1 Company overview
      • 8.3.3.2 Financial performance
      • 8.3.3.3 Product benchmarking
      • 8.3.3.4 Strategic initiatives
    • 8.3.4 Amgen, Inc.
      • 8.3.4.1 Company overview
      • 8.3.4.2 Financial performance
      • 8.3.4.3 Product benchmarking
      • 8.3.4.4 Strategic initiatives
    • 8.3.5 F. Hoffman-La Roche Ltd.
      • 8.3.5.1 Company overview
      • 8.3.5.2 Financial performance
      • 8.3.5.3 Product benchmarking
      • 8.3.5.4 Strategic initiatives
    • 8.3.6 LG Life Sciences Ltd.
      • 8.3.6.1 Company overview
      • 8.3.6.2 Financial performance
      • 8.3.6.3 Product benchmarking
      • 8.3.6.4 Strategic initiatives
    • 8.3.7 Biocon Limited
      • 8.3.7.1 Company overview
      • 8.3.7.2 Financial performance
      • 8.3.7.3 Product benchmarking
      • 8.3.7.4 Strategic initiatives
    • 8.3.8 Intas Pharmaceuticals Ltd.
      • 8.3.8.1 Company overview
      • 8.3.8.2 Financial performance
      • 8.3.8.3 Product benchmarking
      • 8.3.8.4 Strategic initiatives
    • 8.3.9 Sun Pharmaceutical Industries Ltd.
      • 8.3.9.1 Company overview
      • 8.3.9.2 Financial performance
      • 8.3.9.3 Product benchmarking
      • 8.3.9.4 Strategic initiatives
    • 8.3.10 Dr. Reddy's Laboratories Ltd.
      • 8.3.10.1 Company overview
      • 8.3.10.2 Financial performance
      • 8.3.10.3 Product benchmarking
      • 8.3.10.4 Strategic initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
  • TABLE 3 North America erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 4 North America erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 5 North America erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 6 U.S. erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 7 U.S. erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 8 U.S. erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 9 Canada erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 10 Canada erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 11 Canada erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 12 Europe erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
  • TABLE 13 Europe erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 14 Europe erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 15 Europe erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 16 Germany erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 17 Germany erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 18 Germany erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 19 UK erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 20 UK erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 21 UK erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 22 Asia Pacific erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
  • TABLE 23 Asia Pacific erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 24 Asia Pacific erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 25 Asia Pacific erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 26 Japan erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 27 Japan erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 28 Japan erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 29 China erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 30 China erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 31 China erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 32 India erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 33 India erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 34 India erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 35 Latin America erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
  • TABLE 36 Latin America erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 37 Latin America erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 38 Latin America erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 39 Brazil erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 40 Brazil erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 41 Brazil erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 42 Mexico erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 43 Mexico erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 44 Mexico erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 45 MEA erythropoietin drugs market, by country, 2014 - 2025 (USD Million)
  • TABLE 46 MEA erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 47 MEA erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 48 MEA erythropoietin drugs market, by application, 2014 - 2025 (USD Million)
  • TABLE 49 South Africa erythropoietin drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 50 South Africa erythropoietin drugs market, by product, 2014 - 2025 (USD Million)
  • TABLE 51 South Africa erythropoietin drugs market, by application, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends &outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Key opportunities prioritized, by product
  • FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 8 Porter's Five Forces Analysis
  • FIG. 9 Erythropoietin drugs market, drug class outlook: Key takeaways
  • FIG. 10 Erythropoietin drugs market: drug class movement analysis
  • FIG. 11 Biologics market, 2014 - 2025 (USD Million)
  • FIG. 12 Biosimilars market, 2014 - 2025 (USD Million)
  • FIG. 13 Erythropoietin drugs market, product outlook: Key takeaways
  • FIG. 14 Erythropoietin drugs market: Product movement analysis
  • FIG. 15 Epoetin-alfa market, 2014 - 2025 (USD Million)
  • FIG. 16 Epoetin-beta market, 2014 - 2025 (USD Million)
  • FIG. 17 Darbepoetin-alfa market, 2014 - 2025 (USD Million)
  • FIG. 18 Others market, 2014 - 2025 (USD Million)
  • FIG. 19 Erythropoietin drugs market, application outlook: Key takeaways
  • FIG. 20 Erythropoietin drugs market: Application movement analysis
  • FIG. 21 Cancer market, 2014 - 2025 (USD Million)
  • FIG. 22 Hematology market, 2014 - 2025 (USD Million)
  • FIG. 23 Renal diseases market, 2014 - 2025 (USD Million)
  • FIG. 24 Neurology market, 2014 - 2025 (USD Million)
  • FIG. 25 Regional market place: Key takeaways
  • FIG. 26 Regional outlook, 2016 & 2025
  • FIG. 27 Strategy framework
  • FIG. 28 Market participation and categorization
Back to Top